C4x Discovery Share Price (C4XD)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.75 -3.7% 19.50 199,344 13:33:34
Bid Price Offer Price High Price Low Price Open Price
19.00 20.00 20.25 19.50 20.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -13.62 -18.82 25
Last Trade Time Trade Type Trade Size Trade Price Currency
16:48:11 O 25,000 19.00 GBX
Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Motif Bio (MTFB), Bermele (BERM)

C4x Discovery (C4XD) Latest News

C4x Discovery News

Date Time Source Headline
12/11/202012:32UKREGC4X Discovery Holdings PLC Holding(s) in Company
12/11/202011:36UKREGC4X Discovery Holdings PLC Holding(s) in Company
12/11/202009:14UKREGC4X Discovery Holdings PLC Holdings in Company
11/11/202018:12UKREGC4X Discovery Holdings PLC Holdings in Company
11/11/202016:44UKREGC4X Discovery Holdings PLC Holding(s) in Company
09/11/202011:24UKREGC4X Discovery Holdings PLC Result of General Meeting and Issue of Equity
22/10/202019:33ALNCIN BRIEF: Adams Invests GBP700,000 In C4X Discovery's Fund Raise
21/10/202015:12ALNCIN BRIEF: C4X Discovery Raises GBP15 Million Through Share Placing
21/10/202014:54UKREGC4X Discovery Holdings PLC Result of Placing
21/10/202006:06UKREGC4X Discovery Holdings PLC Proposed Placing
More C4x Discovery News
C4x Discovery Investors    C4x Discovery Takeover Rumours

C4x Discovery (C4XD) Discussions and Chat

C4x Discovery Forums and Chat

Date Time Title Posts
01/12/202014:23C4X Discovery Holdings plc2,323

Add a New Thread

C4x Discovery (C4XD) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all C4x Discovery trades in real-time

C4x Discovery (C4XD) Top Chat Posts

DateSubject
01/12/2020
08:20		C4x Discovery Daily Update: C4x Discovery Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker C4XD. The last closing price for C4x Discovery was 20.25p.
C4x Discovery Holdings Plc has a 4 week average price of 18.50p and a 12 week average price of 15p.
The 1 year high share price is 26.50p while the 1 year low share price is currently 8p.
There are currently 127,176,716 shares in issue and the average daily traded volume is 145,337 shares. The market capitalisation of C4x Discovery Holdings Plc is £24,799,459.62.
Read Full Thread
Reply
30/11/2020
09:14		alloa2003: Emailed C4XD today. Lets see if I get a reply:- I am an investor in C4XD and have been since the heady days when the shares were 50p+. During the last 12 months we have seen numerous fund raisings which have diluted private investors with the constant promise these funds will result in a stronger business. So far we have had next to no updates on existing treatments let alone any new ones, we have heard endless promises that partnership deals are in the offing but absolutely nothing to report. As a concept I believe strongly in this company but your PR skills are atrocious and the only winners lately have been the institutions taking on cheap stock at our expense. When can we expect any meaningful updates? When can we expect to see progress? I notice that Mr Dix is involved in a government Covid research project. At the moment it looks as though this is to the severe detriment of the company. If that is the case, you need to find a replacement asap to push the company along. A company that has raised a relatively huge amount of money lately which is disappearing each month with, so far, absolutely nothing to show for it. Unless results are forthcoming, I very much doubt the market will accept another fund raising even at the hugely dilutive levels which seem to have become the norm with C4XD.
Read Full Thread
Follow
Reply
31/10/2020
13:04		the stigologist: Missed this in first reading In August 2020, the Company announced that significant progress has been made on C4XD’s early oral inhibitor programme targeting α4β7 integrin for the treatment of IBD. Effective antibody therapy against this target is already approved, removing the clinical target risk, but effective oral therapy remains highly sought after. C4XD has identified a second series of novel, potent and selective inhibitors providing a further competitive edge for this programme. This reaffirms the capability of C4XD’s Conformetrix technology to discover novel chemical scaffolds for high-value challenging drug targets. Both series have recently demonstrated oral bioavailability in PK studies with the current focus on improving PK properties to demonstrate functional inhibition of α4β7 integrin in vivo following oral dosing. The Company is currently generating improved molecules to move to in vivo studies and despite being early stage, the Company is in discussion with several potential partners, which are under CDA.
Read Full Thread
Follow
Reply
28/10/2020
11:46		alloa2003: I agree this company has the potential to be valued in the hundreds of millions of pounds but it will take more than a "simple sentiment switch". Once they deliver on the next INDV payment that will improve sentiment then we need to see regular deals and regular income. The key to a higher share price here is milestone payments going forward and royalties on all deals. This will increase the cumulative cash flow which will make the company self-funding, delivering more and more treatments going forward.
Read Full Thread
Follow
Reply
28/10/2020
09:29		the stigologist: C4XD Shares in Issue : 226m Share Price : 20p Mkt Cap : £45m Cash : c.£20m EV : £25m Potential milestones on INDV2000 : $294m 11 Drug Discovery programmes 2 late stage programmes which they are looking to licence for same ball park figures as INDV deal You could easily see this Company being valued in the Hundreds of Millions with a simple sentiment switch
Read Full Thread
Follow
Reply
22/10/2020
19:52		the stigologist: hmm Richard Griffiths buying back DDDD a few days back... then they announce NASDAQ list which will massively increase valuation now he's buying C4XD (which also have 4D top two guys involved) Will C4XD look at doing a NASDAQ dual list as well ? I suspect this Company would go down (UP!) brilliantly with US tech investors... tie it in with INDV progressing INDV2000 (C4X32_56) and job's a good un htTps://www.c4xdiscovery.com/news/in-the-news.html
Read Full Thread
Follow
Reply
21/10/2020
17:42		golden prospect: Thanks for that update timbo003; much appreciated. The highest volume in over 3 years has been recorded today with 5.4m and the last booked trade shows 3.385m at 15.75p; the share price closed unchanged on the day.
Read Full Thread
Follow
Reply
21/10/2020
13:50		t0pgrader: The writing was on the wall when most of the institutions top-sliced a few months ago. BUT they didnt sell out. Will be adding if / when share price dips below placing price
Read Full Thread
Follow
Reply
25/8/2020
21:20		the stigologist: Perfectly normal for Deputy Chair of UK Vaccine Taskforce to speak to Bill Gates Interestingly Bill Gates is one of biggest investors in Schrodinger (SDGR) Mkt Cap $5bn Schrodinger is the nearest equivalent to C4XD IF C4XD share price doesn't go up soon I can see a US Company snapping them up for 100p+ The Indivior deal alone at $294m makes C4XD cheap at 100p (c.£130m Mkt Cap) Clive today told us the NRF2/IL17/a4B7 projects have similar potential
Read Full Thread
Follow
Reply
25/8/2020
06:07		alloa2003: Nice update with a mention of work in the area of Covid-19:- 25 August 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today provides a business update. Clive Dix, CEO of C4XD, commented: "I am delighted to share the progress we have made over recent months across our proprietary portfolio despite the challenges of the COVID-19 pandemic, in particular, the continued headway in our key inflammation programmes. Importantly, Indivior recently commenced a Phase 1 clinical trial with our selective Orexin-1 antagonist, C4X_3256, for the treatment of opioid dependence and we eagerly await those results in due course. Our two most advanced programmes, NRF-2 and IL-17, continue to move forward with one of our lead NRF-2 molecules, C4X_6746, showing significant efficacy in a pre-clinical model of Inflammatory Bowel Disease (IBD). This enables expansion of our commercial discussions beyond those partners already engaged in assessing the programme for Pulmonary Arterial Hypertension and Sickle Cell Disease. "We are also pleased to announce a new partnership with the GEN-COVID Consortium in Italy. The collaboration will utilise Taxonomy3® to examine genetic data from a significant number of COVID-19 patients to identify genes specifically associated with severe COVID-19 disease. The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis. This is a new area for C4XD and we are excited to be working on such an important project. We remain committed to deliver and drive novel small molecule drugs against challenging targets towards clinical development." C4XD has continued to make progress across key programmes in its portfolio: · Indivior has commenced a Phase 1 clinical trial for C4XD's novel selective Orexin-1 antagonist, C4X_3256 (also known as INDV-2000), for the treatment of opioid dependence with the first patient now dosed (hxxps://www.clinicaltrials.gov/ct2/show/NCT04413552). This single ascending dose study in healthy volunteers is anticipated to complete by year end. · One of C4XD's lead NRF-2 activator molecules C4X_6746, has recently been shown to significantly inhibit the disease score in a pre-clinical model of IBD in a dose-related manner. Candidate nomination studies continue. · The lead optimisation stage has been initiated for C4XD's novel oral IL-17 inhibitor programme for the treatment of Psoriasis with the aim of identifying further improved small molecules to drive towards a pre-clinical candidate shortlist. We note that Leo Pharma A/S has recently announced that it has identified the first oral IL-17 inhibitor IND-ready candidate with clinical studies expected to be initiated soon. This provides further confidence that the challenge of developing a small molecule alternative to injectable monoclonal antibodies to target IL-17 can be achieved and there has been increased interest from potential pharma partners. · Significant progress has been made on C4XD's early oral inhibitor programme targeting a4b7 integrin for the treatment of IBD. Effective antibody therapy against this target is already approved, removing the clinical target risk, but effective oral therapy remains highly sought after. C4XD has identified a second series of novel, potent and selective inhibitors providing a further competitive edge for this programme. This reaffirms the capability of C4XD's Conformetrix technology to discover novel chemical scaffolds for high-value challenging drug targets. Both series have recently demonstrated oral bioavailability in PK studies with the current focus on improving PK properties to demonstrate functional inhibition of a4b7 integrin in vivo following oral dosing. · The LifeArc risk-share collaboration on an oral small molecule inhibitor programme for the treatment of haematological cancers and inflammatory disease continues to progress well despite being impacted by COVID-19. Three novel series have been identified by harnessing C4XD's Conformetrix technology and recent data has demonstrated functional cell activity and oral bioavailability for all three series. Optimisation continues with the aim of demonstrating functional inhibition of the target in vivo following oral dosing. · C4XD has recently entered a new collaboration with the GEN-COVID consortium, a network of more than 20 hospitals in Italy led by Professor Alessandra Renieri of the University of Siena. The collaboration will use the unique mathematical genetic analysis methodology of Taxonomy3® to investigate the role genetics plays in the widely varied disease susceptibility, severity and prognosis observed between individuals with COVID-19. Taxonomy3® will analyse genetic data from a significant number of COVID-19 positive patients collected by the consortium to identify genes associated with severe COVID-19 disease. The aim is to identify a unique genetic signature that can successfully predict mild vs. severe disease to inform treatment of patients at risk. The analysis may also uncover novel biology driving severity of the disease which may inform potential novel drug targets for treatment.
Read Full Thread
Follow
Reply
29/6/2020
19:03		the stigologist: The Company updated on both NRF2 and IL17 programmes in results statement From my layman takes extra data studies sounded like i'd guess 3-6 month delay? on NRF2 On IL17 strong interest it seems to be just a case of opting for the best partner presumably they have to make a choice between negotiating when they look desperate or when they look strong (they may be stronger following any INDV / C4X3256 Phase I start and milestone payment) Anyway I expect news from INDV 'imminently' given their CEO change today a Clinical Trial start may be something positive for them to release at last. Oral NRF-2 Activator Programme C4XD is progressing a series of novel potent activators of the NRF-2 pathway for the treatment of Sickle Cell Disease and Pulmonary Arterial Hypertension. In C4XD studies, multiple lead compounds show >12hr duration of action following low oral dosing on activation of NRF-2 in key tissues such as lung and liver, as well as blood. Candidate nomination studies continue and C4XD now has a shortlist of three lead compounds to enable selection of the candidate. Following commercial discussions, the Company is enhancing the data package with additional studies to further support our commercial proposition. Oral IL-17 Inhibitor Programme Interleukin-17 ("IL-17") is a high-value, clinically validated target for inflammation and autoimmune diseases such as psoriasis (estimated to be worth c.$24 billion per annum by 2027 1 ). Current treatments are based on injectable monoclonal antibodies and an oral option would be highly desirable to increase the number of patients able to access IL-17 targeted drugs. Recent data of C4XD ' s prototype lead oral compound demonstrates activity for the first time in IL-17 driven pre-clinical inflammation disease models following oral dosing. C4XD continues to receive strong interest from potential partners for this oral IL-17 inhibitor approach.
Read Full Thread
Follow
Reply
C4x Discovery share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
C4XD
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201201 18:50:53